Effects of MCP-1 inhibition by bindarit therapy in a rat model of polycystic kidney disease

Carlamaria Zoja, Daniela Corna, Monica Locatelli, Daniela Rottoli, Anna Pezzotta, Marina Morigi, Cristina Zanchi, Simona Buelli, Angelo Guglielmotti, Norberto Perico, Andrea Remuzzi, Giuseppe Remuzzi

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Background/Aims: Experimental and clinical evidence suggested that monocyte chemoattractant protein-1 (MCP-1/CCL2) has a role in the development of interstitial inflammation and renal failure in polycystic kidney disease (PKD). We investigated whether bindarit, an inhibitor of MCP-1/CCL2 synthesis, could influence the evolution of PKD in PCK rats. Methods: PCK rats were treated from 5 to 15 weeks of age with vehicle or bindarit. Sprague-Dawley rats served as control. For in vitro studies, murine podocytes were exposed to albumin with or without bindarit. Results: MCP-1 mRNA was upregulated in the kidney of PCK rats and reduced by bindarit. Treatment limited overexpression of MCP-1 protein by epithelial cells of dilated tubules and cysts, and interstitial inflammatory cells. Excessive renal accumulation of mono-cytes/macrophages was lowered by bindarit by 41%. Serum creatinine slightly increased in PCK rats on vehicle and was similar to controls after bindarit. Kidney and liver cysts were not affected by treatment. Bindarit significantly reduced progressive proteinuria of PCK rats. The antiproteinuric effect was associated with the restoration of the defective nephrin expression in podocytes of PCK rats. Bindarit limited podocyte foot process effacement and ameliorated slit diaphragm frequency. In cultured podocytes, bindarit reduced MCP-1 production in response to albumin and inhibited albumin-induced cytoskeletal remodeling and cell migration. Conclusion: This study showed that although bindarit did not prevent renal cyst growth, it limited interstitial inflammation and renal dysfunction and reduced proteinuria in PKD. Thus, bindarit could be considered a therapeutic intervention complementary to therapies specifically acting to block renal cyst growth.

Original languageEnglish
Pages (from-to)52-61
Number of pages10
JournalNephron
Volume129
Issue number1
DOIs
Publication statusPublished - Jan 1 2015

Fingerprint

Polycystic Kidney Diseases
Podocytes
Kidney
Cysts
Therapeutics
Albumins
Proteinuria
bindarit
Inflammation
Chemokine CCL2
Complementary Therapies
Growth
Diaphragm
Cell Movement
Renal Insufficiency
Sprague Dawley Rats
Creatinine
Epithelial Cells
Macrophages

Keywords

  • Bindarit
  • Interstitial inflammation
  • MCP-1
  • PCK rat
  • Podocyte
  • Polycystic kidney disease
  • Proteinuria

ASJC Scopus subject areas

  • Physiology
  • Nephrology
  • Urology
  • Physiology (medical)
  • Medicine(all)

Cite this

Effects of MCP-1 inhibition by bindarit therapy in a rat model of polycystic kidney disease. / Zoja, Carlamaria; Corna, Daniela; Locatelli, Monica; Rottoli, Daniela; Pezzotta, Anna; Morigi, Marina; Zanchi, Cristina; Buelli, Simona; Guglielmotti, Angelo; Perico, Norberto; Remuzzi, Andrea; Remuzzi, Giuseppe.

In: Nephron, Vol. 129, No. 1, 01.01.2015, p. 52-61.

Research output: Contribution to journalArticle

Zoja, C, Corna, D, Locatelli, M, Rottoli, D, Pezzotta, A, Morigi, M, Zanchi, C, Buelli, S, Guglielmotti, A, Perico, N, Remuzzi, A & Remuzzi, G 2015, 'Effects of MCP-1 inhibition by bindarit therapy in a rat model of polycystic kidney disease', Nephron, vol. 129, no. 1, pp. 52-61. https://doi.org/10.1159/000369149
Zoja, Carlamaria ; Corna, Daniela ; Locatelli, Monica ; Rottoli, Daniela ; Pezzotta, Anna ; Morigi, Marina ; Zanchi, Cristina ; Buelli, Simona ; Guglielmotti, Angelo ; Perico, Norberto ; Remuzzi, Andrea ; Remuzzi, Giuseppe. / Effects of MCP-1 inhibition by bindarit therapy in a rat model of polycystic kidney disease. In: Nephron. 2015 ; Vol. 129, No. 1. pp. 52-61.
@article{fcc8e46bacfb4fcf9c6fbc51b9e695d0,
title = "Effects of MCP-1 inhibition by bindarit therapy in a rat model of polycystic kidney disease",
abstract = "Background/Aims: Experimental and clinical evidence suggested that monocyte chemoattractant protein-1 (MCP-1/CCL2) has a role in the development of interstitial inflammation and renal failure in polycystic kidney disease (PKD). We investigated whether bindarit, an inhibitor of MCP-1/CCL2 synthesis, could influence the evolution of PKD in PCK rats. Methods: PCK rats were treated from 5 to 15 weeks of age with vehicle or bindarit. Sprague-Dawley rats served as control. For in vitro studies, murine podocytes were exposed to albumin with or without bindarit. Results: MCP-1 mRNA was upregulated in the kidney of PCK rats and reduced by bindarit. Treatment limited overexpression of MCP-1 protein by epithelial cells of dilated tubules and cysts, and interstitial inflammatory cells. Excessive renal accumulation of mono-cytes/macrophages was lowered by bindarit by 41{\%}. Serum creatinine slightly increased in PCK rats on vehicle and was similar to controls after bindarit. Kidney and liver cysts were not affected by treatment. Bindarit significantly reduced progressive proteinuria of PCK rats. The antiproteinuric effect was associated with the restoration of the defective nephrin expression in podocytes of PCK rats. Bindarit limited podocyte foot process effacement and ameliorated slit diaphragm frequency. In cultured podocytes, bindarit reduced MCP-1 production in response to albumin and inhibited albumin-induced cytoskeletal remodeling and cell migration. Conclusion: This study showed that although bindarit did not prevent renal cyst growth, it limited interstitial inflammation and renal dysfunction and reduced proteinuria in PKD. Thus, bindarit could be considered a therapeutic intervention complementary to therapies specifically acting to block renal cyst growth.",
keywords = "Bindarit, Interstitial inflammation, MCP-1, PCK rat, Podocyte, Polycystic kidney disease, Proteinuria",
author = "Carlamaria Zoja and Daniela Corna and Monica Locatelli and Daniela Rottoli and Anna Pezzotta and Marina Morigi and Cristina Zanchi and Simona Buelli and Angelo Guglielmotti and Norberto Perico and Andrea Remuzzi and Giuseppe Remuzzi",
year = "2015",
month = "1",
day = "1",
doi = "10.1159/000369149",
language = "English",
volume = "129",
pages = "52--61",
journal = "Experimental Nephrology",
issn = "0028-2766",
publisher = "S. Karger AG",
number = "1",

}

TY - JOUR

T1 - Effects of MCP-1 inhibition by bindarit therapy in a rat model of polycystic kidney disease

AU - Zoja, Carlamaria

AU - Corna, Daniela

AU - Locatelli, Monica

AU - Rottoli, Daniela

AU - Pezzotta, Anna

AU - Morigi, Marina

AU - Zanchi, Cristina

AU - Buelli, Simona

AU - Guglielmotti, Angelo

AU - Perico, Norberto

AU - Remuzzi, Andrea

AU - Remuzzi, Giuseppe

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Background/Aims: Experimental and clinical evidence suggested that monocyte chemoattractant protein-1 (MCP-1/CCL2) has a role in the development of interstitial inflammation and renal failure in polycystic kidney disease (PKD). We investigated whether bindarit, an inhibitor of MCP-1/CCL2 synthesis, could influence the evolution of PKD in PCK rats. Methods: PCK rats were treated from 5 to 15 weeks of age with vehicle or bindarit. Sprague-Dawley rats served as control. For in vitro studies, murine podocytes were exposed to albumin with or without bindarit. Results: MCP-1 mRNA was upregulated in the kidney of PCK rats and reduced by bindarit. Treatment limited overexpression of MCP-1 protein by epithelial cells of dilated tubules and cysts, and interstitial inflammatory cells. Excessive renal accumulation of mono-cytes/macrophages was lowered by bindarit by 41%. Serum creatinine slightly increased in PCK rats on vehicle and was similar to controls after bindarit. Kidney and liver cysts were not affected by treatment. Bindarit significantly reduced progressive proteinuria of PCK rats. The antiproteinuric effect was associated with the restoration of the defective nephrin expression in podocytes of PCK rats. Bindarit limited podocyte foot process effacement and ameliorated slit diaphragm frequency. In cultured podocytes, bindarit reduced MCP-1 production in response to albumin and inhibited albumin-induced cytoskeletal remodeling and cell migration. Conclusion: This study showed that although bindarit did not prevent renal cyst growth, it limited interstitial inflammation and renal dysfunction and reduced proteinuria in PKD. Thus, bindarit could be considered a therapeutic intervention complementary to therapies specifically acting to block renal cyst growth.

AB - Background/Aims: Experimental and clinical evidence suggested that monocyte chemoattractant protein-1 (MCP-1/CCL2) has a role in the development of interstitial inflammation and renal failure in polycystic kidney disease (PKD). We investigated whether bindarit, an inhibitor of MCP-1/CCL2 synthesis, could influence the evolution of PKD in PCK rats. Methods: PCK rats were treated from 5 to 15 weeks of age with vehicle or bindarit. Sprague-Dawley rats served as control. For in vitro studies, murine podocytes were exposed to albumin with or without bindarit. Results: MCP-1 mRNA was upregulated in the kidney of PCK rats and reduced by bindarit. Treatment limited overexpression of MCP-1 protein by epithelial cells of dilated tubules and cysts, and interstitial inflammatory cells. Excessive renal accumulation of mono-cytes/macrophages was lowered by bindarit by 41%. Serum creatinine slightly increased in PCK rats on vehicle and was similar to controls after bindarit. Kidney and liver cysts were not affected by treatment. Bindarit significantly reduced progressive proteinuria of PCK rats. The antiproteinuric effect was associated with the restoration of the defective nephrin expression in podocytes of PCK rats. Bindarit limited podocyte foot process effacement and ameliorated slit diaphragm frequency. In cultured podocytes, bindarit reduced MCP-1 production in response to albumin and inhibited albumin-induced cytoskeletal remodeling and cell migration. Conclusion: This study showed that although bindarit did not prevent renal cyst growth, it limited interstitial inflammation and renal dysfunction and reduced proteinuria in PKD. Thus, bindarit could be considered a therapeutic intervention complementary to therapies specifically acting to block renal cyst growth.

KW - Bindarit

KW - Interstitial inflammation

KW - MCP-1

KW - PCK rat

KW - Podocyte

KW - Polycystic kidney disease

KW - Proteinuria

UR - http://www.scopus.com/inward/record.url?scp=84940950180&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940950180&partnerID=8YFLogxK

U2 - 10.1159/000369149

DO - 10.1159/000369149

M3 - Article

VL - 129

SP - 52

EP - 61

JO - Experimental Nephrology

JF - Experimental Nephrology

SN - 0028-2766

IS - 1

ER -